financetom
Business
financetom
/
Business
/
BRIEF-FBS Global Ltd Files To Withdraw US IPO Plans - SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-FBS Global Ltd Files To Withdraw US IPO Plans - SEC Filing
Nov 4, 2024 11:31 AM

Nov 4 (Reuters) - FBS Global Ltd:

* FBS GLOBAL LTD FILES TO WITHDRAW US IPO PLANS - SEC

FILING

* FBS GLOBAL LTD - HAD PREVIOUSLY FILED FOR US IPO IN AUGUST

2024

Source text:

Further company coverage:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Levi Strauss Fiscal Q3 Adjusted Earnings, Net Revenue Rise
Levi Strauss Fiscal Q3 Adjusted Earnings, Net Revenue Rise
Oct 2, 2024
04:34 PM EDT, 10/02/2024 (MT Newswires) -- Levi Strauss (LEVI) reported fiscal Q3 adjusted earnings late Wednesday of $0.33 per diluted share, up from $0.28 a year earlier. Analysts polled by Capital IQ expected $0.31. Net revenue in the quarter ended Aug. 25 rose to $1.52 billion from $1.51 billion a year earlier. Analysts surveyed by Capital IQ expected $1.55...
Radiant Logistics Acquires Focus Logistics
Radiant Logistics Acquires Focus Logistics
Oct 2, 2024
04:38 PM EDT, 10/02/2024 (MT Newswires) -- Radiant Logistics ( RLGT ) said late Wednesday it has acquired Focus Logistics, which has operated under the company's Service By Air brand since 2006 and is now expected to transition to the Radiant brand. The purchase price is payable in subsequent periods based on the future performance of Focus Logistics, Radiant said....
Arcus Biosciences, AstraZeneca Collaborate on Developing Carcinoma Treatment
Arcus Biosciences, AstraZeneca Collaborate on Developing Carcinoma Treatment
Oct 2, 2024
04:37 PM EDT, 10/02/2024 (MT Newswires) -- Arcus Biosciences ( RCUS ) said Wednesday it is collaborating with AstraZeneca ( AZN ) in a clinical trial to evaluate a combination of casdatifan with volrustomig to treat patients with clear cell renal cell carcinoma. Casdatifan is Arcus's investigational and volrustomig is AstraZeneca's ( AZN ) investigational PD-1/CTLA-4 bispecific antibody. This is...
OpenAI tells investor to not invest in five AI startups including Sutskever's SSI
OpenAI tells investor to not invest in five AI startups including Sutskever's SSI
Oct 2, 2024
(Reuters) - As global investors such as Thrive Capital and Tiger Global invest $6.6 billion in OpenAI, the ChatGPT-maker sought a commitment beyond just capital - they also wanted investors to refrain from funding five companies they perceive as close competitors, sources told Reuters. The list of companies includes rivals developing large language models such as Anthropic and Elon Musk's...
Copyright 2023-2026 - www.financetom.com All Rights Reserved